123 Acurae Pharma GmbH secures contract for Pharmaceutical products conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Rivaroxaban, ATC B01AF01 for the period 01042024 - 31032025 (plus extension option 1x12 months)

Germany, June 24 -- Germany based 123 Acurae Pharma GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Rivaroxaban, ATC B01AF01 for the period 01042024 - 31032025 (plus extension option 1x12 months) . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....